← Volver a la portada
Oceanía · Mercados regionales · Stockhead

Dr Boreham’s Crucible: Revenge of the nerd – Percheron’s new boss takes on cancer

Publicado por Stockhead · Australia hace 5 h
Dr Boreham’s Crucible: Revenge of the nerd – Percheron’s new boss takes on cancer
Stockhead

Resumen detallado

Self-confessed science nerd Dr Michael Baker has restarted the engine of Percheron Therapeutics with the aim of getting the oncology ... Read More The post Dr Boreham’s Crucible:…

Percheron has revived itself as an oncology play. Pic: Tim Boreham/supplied

Dr Michael Baker, the new CEO of Percheron Therapeutics (ASX:PER), describes himself as “pretty boring, but in a good way”.

“I just love high-quality science with a disproportionate chance of success in a field I have a tremendous interest in.”

Boring? We would still strike up a chat with him at a party, albeit after a second drink.

This alleged dullness made Baker a walk-up start to head Percheron, which has revived itself as an oncology play after a catastrophic Duchenne muscular dystrophy trial (see below).

Baker was fresh from a six-year stint at Arovella Therapeutics, which he re-engineered from unsuccessful spray-delivery drug play Suda Pharmaceuticals to an early-stage cancer cell therapy developer.

Baker’s Percheron appointment is also notable because he eschewed a number of better-paid, bigger roles for the buzz of early-stage drug development.

“I don’t want to sound like a twerp, but I was quite lucky in that I got a number of opportunities to explore and some of them were quite sizeable,” he said.

“They had a lot of money, [but] I actually didn’t find it all that interesting.

Inicio del artículo, extracto de Stockhead. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en Stockhead Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (stockhead.com.au)

También te puede interesar